Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy

References

• Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–165.
   PubMed Web of Science ®Google Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109.
   PubMed Web of Science ®Google Scholar
• Rowley JD. The critical role of chromosome translocations in human leukemias. Annu Rev Genet. 1998;32:495–519. 1
   PubMedGoogle Scholar
• Meenakshi C, Venkatraman B Correlation between cytogenetic biomarkers obtained from DC and CBMN assays caused by low dose radon exposure in smokers. Int J Radiat Biol. 2019 Sep;95(9):1268–1275. Epub 2019 Jun 11. PMID: 31145026.
   PubMed Web of Science ®Google Scholar
• Tuna M, Amos CI, Mills GB. Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors. Oncotarget. 2019;10(21):2095–2111.
   PubMedGoogle Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Alì G, Bruno R, Savino M, et al. Analysis of fusion genes by nanostring system: a role in lung cytology? Arch Pathol Lab Med. 2018;142(4):480–489.
   PubMed Web of Science ®Google Scholar
• Watson IR, Takahashi K, Futreal PA, et al. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14(10):703–18.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Wang Q, Torres-Garcia W, et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34(37):4845–4854.
   PubMed Web of Science ®Google Scholar
• Gao Q, Liang WW, Foltz SM, et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 2018;23(1):227–238. e3.
   PubMed Web of Science ®Google Scholar
• Latysheva NS, Babu MM. Molecular signatures of fusion proteins in cancer. ACS Pharmacol Transl Sci. 2019;2(2):122–133.
   PubMedGoogle Scholar
• Kazandjian D, Blumenthal GM, Luo L, et al. Summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer. Oncologist. 2016;21(8):974–980.
   PubMed Web of Science ®Google Scholar
• Huang Q, Schneeberger VE, Luetteke N, et al. Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma. Mol Cancer Ther. 2016;15(10):2521–2529.
   PubMed Web of Science ®Google Scholar
• Zito Marino F, Pagliuca F, Ronchi A, et al. NTRK fusions, from the diagnostic algorithm to innovative treatment in the era of precision medicine. Int J Mol Sci. 2020;21(10):3718.
   Web of Science ®Google Scholar
• Cozzolino I, Ronchi A, Messina G, et al. Adequacy of cytologic samples by ultrasound-guided percutaneous transthoracic fine-needle aspiration cytology of peripheral pulmonary nodules for morphologic diagnosis and molecular evaluations: comparison with computed tomography-guided percutaneous transthoracic fine-needle aspiration cytology. Arch Pathol Lab Med. 2020;144(3):361–369.
   PubMed Web of Science ®Google Scholar
• Kerr KM, López-Ríos F. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol. 2016;27 Suppl 3:iii16–iii24.
   PubMedGoogle Scholar
• Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update. J Clin Oncol. 2018;36(9):911–919.
   PubMed Web of Science ®Google Scholar
• Li W, Liu Y, Li W, et al.. Intergenic breakpoints identified by dna sequencing confound targetable kinase fusion detection in NSCLC. J Thorac Oncol. 2020;15(7):1223–1231.
   PubMed Web of Science ®Google Scholar
• Teixido C, Karachaliou N, Peg V, et al. Concordance of IHC, FISH, and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res. 2014;3(2):70–74.
   PubMedGoogle Scholar
• Vaughn CP, Costa JL, Feilotter HE, et al. Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. BMC Cancer. 2018;18:828. 1
   PubMedGoogle Scholar
• Gruber K, Horn H, Kalla J, et al. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay. J Thorac Oncol. 2014;9(3):307–315.
   PubMed Web of Science ®Google Scholar
• Sheikine Y, Kuo FC, Lindeman NI. Clinical and technical aspects of genomic diagnostics for precision oncology. J Clin Oncol. 2017;35:929–933. 9
   PubMed Web of Science ®Google Scholar
• Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374:54–61. 1
   PubMed Web of Science ®Google Scholar
• Mellert HS, Alexander KE, Jackson LP, et al. A blood-based test for the detection of ROS1 and RET fusion transcripts from circulating ribonucleic acid using digital polymerase chain reaction. J Vis Exp. 2018;(134):57079.
   Google Scholar
• Drilon A, Wang L, Arcila MA, et al. Broad, hybrid capture-based next generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res. 2015;21:3631–3639. 16
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566. 7153
   PubMed Web of Science ®Google Scholar
• Thunnissen E, Bubendorf L, Dietel M, et al. EML-4-ALK testing in NSCLC of the lung: a review with recommendations. Virchows Arch. 2012;461:245–257. 3
   PubMed Web of Science ®Google Scholar
• Soda M, Isobe K, Inoue A, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non–small cell lung cancer. Clin Cancer Res. 2012;18:5682–5689. 20
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of american pathologists, the international association for the study of lung cancer, and the association for molecular pathology. J Mol Diagn. 2018;20:129–159. 2
   PubMed Web of Science ®Google Scholar
• Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016;11:487–495. 4
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Togashi Y, Kamihara Y, et al.. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol. 2016 Jan;27(1):185–192. Epub 2015 Oct 20. PMID: 26487585; PMCID: PMC4684157.
   PubMed Web of Science ®Google Scholar
• List of cleared or approved companion diagnostic devices (In vitro and imaging tools) [Internet]. [cited 2021 Mar 4]. Available from: www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools/
   Google Scholar
• Clavé S, Rodon N, Pijuan L, et al. Next-generation sequencing for ALK and ROS1 rearrangement detection in patients with non-small-cell lung cancer: implications of FISH-positive patterns. Clin Lung Cancer. 2019;20(4):e421–e429.
   PubMed Web of Science ®Google Scholar
• Evangelista AF, Zanon MF, Carloni AC, et al. Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology. BMC Pulm Med. 2017;17:86. 1
   PubMedGoogle Scholar
• Cortinovis D, Canova S, Abbate MI, et al. Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse. Future Oncol. 2018;14:2303–2317. 22
   PubMed Web of Science ®Google Scholar
• FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC [Internet]. [cited 2021 Mar 4]. Available from: https://www.fda.gov/drugs/fda-approves-lorlatinib-second-or-third-line-treatment-alk-positive-metastatic-nsclc
   Google Scholar
• Drilon A, Jenkins C, Iyer S, et al. ROS1-dependent cancers — biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021 Jan;18(1):35-55.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J Thorac Oncol. 2017;12(11):1611–1625.
   PubMed Web of Science ®Google Scholar
• Zong CS, Zeng L, Jiang Y, et al. Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem. 1998;273(43):28065–28072.
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Zong CS, Uttamsingh S, et al. The role of phosphatidylinositol 3-kinase, Rho family GTPases, and STAT3 in Ros-induced cell transformation. J Biol Chem. 2002;277(13):11107–11115.
   PubMed Web of Science ®Google Scholar
• Neel DS, Allegakoen DV, Olivas V, et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Res. 2019;79(3):546–556.
   PubMed Web of Science ®Google Scholar
• Rossi G, Jocolle G, Conti A, et al. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. Lung Cancer (Auckl). 2017;8:45e55.
   Google Scholar
• Bubendorf L, Büttner R, Al-Dayel F, et al. Testing for ROS1 in non–small cell lung cancer: a review with recommendations. Virchows Arch. 2016;469(5):489–503.
   PubMed Web of Science ®Google Scholar
• Sung S, Heymann JJ, Crapanzano JP, et al. Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. J Am Soc Cytopathol. 2020;9(5):332–345.
   PubMedGoogle Scholar
• Zito Marino F, Rossi G, Cozzolino I, et al. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples. J Clin Pathol. 2020;73(2):96–101.
   PubMed Web of Science ®Google Scholar
• Bozzetti C, Nizzoli R, Tiseo M, et al. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. Diagn Cytopathol. 2015;43(11):941–946.
   PubMed Web of Science ®Google Scholar
• Conde E, Hernandez S, Martinez R, et al. Assessment of a new ROS1 immunohistochemistry clone (SP384) for the identification of ROS1 rearrangements in patients with non-small cell lung carcinoma: the ROSING study. J Thorac Oncol. 2019;14(12):2120–2132.
   PubMed Web of Science ®Google Scholar
• Huang RSP, Smith D, Le CH, et al. Correlation of ROS1 immunohistochemistry with ROS1 fusion status determined by fluorescence in situ hybridization. Arch Pathol Lab Med. 2020;144(6):735–741.
   PubMed Web of Science ®Google Scholar
• Wang W, Cheng G, Zhang G, et al. Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer. Lung Cancer. 2020;146:224–229.
   PubMed Web of Science ®Google Scholar
• Hofman V, Rouquette I, Long-Mira E, et al. Multicenter evaluation of a novel ROS1 immunohistochemistry assay (SP384) for detection of ROS1 rearrangements in a large cohort of lung adenocarcinoma patients. J Thorac Oncol. 2019;14(7):1204–1212.
   PubMed Web of Science ®Google Scholar
• Rogers T-M, Arnau GM, Ryland GL, et al. Multiplexed transcriptome analysis to detect ALK, ROS1, and RET rearrangements in lung cancer. Sci Rep. 2017;7:42259. 1
   PubMedGoogle Scholar
• Reguart N, Teixido C, Gimenez-Capitan A, et al. Identification of ALK, ROS1, and RET fusions by a multiplexed mRNAbased assay in formalin-fixed, paraffin-embedded samples from advanced non-small-cell lung cancer patients. Clin Chem. 2017;63:751e760. 3
   Web of Science ®Google Scholar
• Lira ME, Choi YL, Lim SM, et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn. 2014;16:229–243. 2
   PubMed Web of Science ®Google Scholar
• Davies KD, Le AT, Sheren J, et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J Thorac Oncol. 2018;13(10):1474–1482.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 2016;14:255–264.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group. Ann Oncol. 2020;S0923–7534(20)39971–39973.
   Google Scholar
• Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121–1126.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):261–270.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SHI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7:400–409. 4
   PubMed Web of Science ®Google Scholar
• Lim SM, Kim HR, Lee JS, et al. Open-Label, multicenter, phase ii study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613–2618.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis Oncol. 2017;2017: PO.17.00063.
   PubMedGoogle Scholar
• Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2019;20(12):1691–1701.
   PubMed Web of Science ®Google Scholar
• Cho BC, Drilon AE, Doebele RC, et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). J Clin Oncol. 2019;37(Suppl:15):9011.
   Web of Science ®Google Scholar
• Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42:581–588. 2
   PubMed Web of Science ®Google Scholar
• Takahashi M. Ret protooncogene and human-diseases – review. Int J Oncol. 1994;4:81–84. 1
   PubMed Web of Science ®Google Scholar
• Ishizaka Y, Itoh F, Tahira T, et al. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene. 1989;4:1519–1521.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18,378–381. 3
   PubMed Web of Science ®Google Scholar
• Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12:192–202. 4
   PubMed Web of Science ®Google Scholar
• Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET protooncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–856. 7
   PubMed Web of Science ®Google Scholar
• Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375–376. 6461
   PubMed Web of Science ®Google Scholar
• Raue F, Frank-Raue K. Thyroid cancer: risk-stratified management and individualized therapy. Clin Cancer Res. 2016;22:5012–5021. 20
   PubMed Web of Science ®Google Scholar
• Gautschi O, Milia J, Filleron T, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter registry. J Clin Oncol. 2017;35:1403–1410. 13
   PubMed Web of Science ®Google Scholar
• Drilon A, Hu Z, Lai G, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151–167.
   PubMed Web of Science ®Google Scholar
• Chao BH, Briesewitz R, Villalona-Calero MA. RET fusion genes in non–small-cell lung cancer. J Clin Oncol. 2012;30:4439–4441. 35
   PubMed Web of Science ®Google Scholar
• Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014;14:173–186. 3
   PubMed Web of Science ®Google Scholar
• Kohno T, Ichikawa H, Totoki Y, et al. KIF5B–RET fusions in lung adenocarcinoma. Nat Med. 2012;18:375–377. 3
   PubMed Web of Science ®Google Scholar
• Wang R, Hu H, Panet Y, et al. RET Fusions define a unique molecular and clinicopathologic subtype of non–small-cell lung cancer. J Clin Oncol. 2012;30:4352–4359. 35
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3:630–635. 6
   PubMed Web of Science ®Google Scholar
• Platt A, Morten J, Ji Q, et al. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized phase III studies. BMC Cancer. 2015;15:171. 1
   PubMedGoogle Scholar
• Go H, Jung YJ, Kang HW, et al. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma. Lung Cancer. 2013;82:44–50. 1
   PubMed Web of Science ®Google Scholar
• Tsuta K, Kohno T, Yoshida A, et al. RET-rearranged non small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer. 2014;110:1571–1578. 6
   PubMed Web of Science ®Google Scholar
• Ferrara R, Auger N, Auclin E, et al. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. J Thorac Oncol. 2018;13:27–45. 1
   PubMed Web of Science ®Google Scholar
• Tan AC, Seet AOL, Lai GGY, et al. Molecular characterization and clinical outcomes in RET-rearranged NSCLC. J Thorac Oncol. 2020;15(12):1928–1934.
   PubMed Web of Science ®Google Scholar
• Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016;17(12):1653–1660.
   PubMed Web of Science ®Google Scholar
• Yoh K, Seto T, Satouchiet M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2017;5:42–50. 1
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2017;28:292–297. 2
   PubMed Web of Science ®Google Scholar
• Plenker D, Riedel M, Brägelmann J, et al. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Sci Transl Med. 2017;9(394):eaah6144.
   PubMed Web of Science ®Google Scholar
• Drilon A, Li G, Dogan S, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27(5):920–926.
   PubMed Web of Science ®Google Scholar
• FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions [Internet]. [cited 2021 Mar 4]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions
   Google Scholar
• FDA approves pralsetinib for lung cancer with RET gene fusions [Internet]. [cited 2021 Mar 4]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions
   Google Scholar
• Solomon BJ, Tan L, Lin JJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol. 2020;15:541–549. 4
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Bencardino K, et al.et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;30(Suppl_8):viii5.
   PubMedGoogle Scholar
• Stephens RM, Loeb DM, Copeland TD, et al. Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses. Neuron. 1994;12,691–705. 3
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469–1472.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Brambilla M, Metro G, et al. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Med Oncol. 2017;34(6):105.
   PubMed Web of Science ®Google Scholar
• Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. JCO Precis Oncol. 2018;2018:PO.18.00037. 
   Web of Science ®Google Scholar
• De Winne K, Sorber L, Lambin S, et al. immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial. Virchows Arch. 2020. 10.1007/s00428-020-02921-6
   PubMed Web of Science ®Google Scholar
• Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38–46.
   PubMed Web of Science ®Google Scholar
• Hechtman JF, Benayed R, Hyman DM, et al. Pan-Trk immunohistochemistry is an E_cient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41:1547–1551. 11
   PubMed Web of Science ®Google Scholar
• Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.Ann Oncol. 2019;30:1417–1427. 9
   PubMed Web of Science ®Google Scholar
• Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7(9):963–972.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Chmielecki J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138(4):881–890.
   PubMed Web of Science ®Google Scholar
• Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4(4):415–422.
   PubMed Web of Science ®Google Scholar
• Wang R, Wang L, Li Y, et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res. 2014;20(15):4107–4114.
   PubMed Web of Science ®Google Scholar
• Konduri K, Gallant JN, Chae YK, et al. EGFR Fusions as novel therapeutic targets in lung cancer. Cancer Discov. 2016;6(6):601–611.
   PubMed Web of Science ®Google Scholar
• Nakaoku T, Tsuta K, Ichikawa H, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014;20(12):3087–3093.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang Y, Ye T, et al. Detection of Novel NRG1, EGFR, and MET fusions in lung adenocarcinomas in the chinese population. J Thorac Oncol. 2019;14(11):2003–2008.
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Ou SI. Neuregulin 1 fusion-positive NSCLC. J Thorac Oncol. 2019;14(8):1354–1359.
   PubMed Web of Science ®Google Scholar
• Qin A, Johnson A, Ross JS, et al. Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling. J Thorac Oncol. 2019;14(1):54–62.
   PubMed Web of Science ®Google Scholar
• Jonna S, Feldman RA, Swensen J, et al. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019;25(16):4966–4972.
   PubMed Web of Science ®Google Scholar
• Kim HS, Han JY, Shin DH, et al. EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion. Lung Cancer. 2018;124:71–75.
   PubMed Web of Science ®Google Scholar
• Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636–647.
   PubMed Web of Science ®Google Scholar
• Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793–798.
   PubMed Web of Science ®Google Scholar
• Farago AF, Azzoli CG. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. Transl Lung Cancer Res. 2017;6(5):550–559.
   PubMed Web of Science ®Google Scholar
• Liang W, He Q, Chen Y, et al. Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report. BMC Cancer. 2016;16:62. 1
   PubMedGoogle Scholar
• Schrock AB, Zhu VW, Hsieh WS, et al. Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2018;13(9):1312–1323.
   PubMed Web of Science ®Google Scholar
• FDA approves first liquid biopsy next-generation sequencing companion diagnostic test [Internet]. [cited 2021 Mar 4]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test/
   Google Scholar
• FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers [Internet]. [cited 2021 Mar 4]. Available from: https://www.fda.gov/drugs/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers
   Google Scholar
• Cheng DT, Mitchell TN, Zehir A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251–264.
   PubMed Web of Science ®Google Scholar
• Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2013;31(18):2273–2281.
   PubMed Web of Science ®Google Scholar
• Zito Marino F, Rossi G, Brunelli M, et al. Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: cytological smears versus cell blocks: ALK rearrangement in cytological samples. Cancer Cytopathol. 2017;125(5):303–312.
   PubMed Web of Science ®Google Scholar
• Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–713.
   PubMed Web of Science ®Google Scholar
• Schram AM, Chang MT, Jonsson P, et al. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol. 2017;14(12):735–748.
   PubMed Web of Science ®Google Scholar
• Dall’Olio FG, Conci N, Rossi G, et al. Comparison of sequential testing and next generation sequencing in advanced lung adenocarcinoma patients - A single centre experience. Lung Cancer. 2020;149:5–9.
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173–180.
   PubMed Web of Science ®Google Scholar
• Tsao MS, Hirsh FR, Yatabe Y, editors. IASLC Atlas of ALK and ROS1 testing in lung cancer. 2nd ed. Fort Meyers: Editorial Rx Press; 2016.
   Google Scholar
• Uruga H, Mino-Kenudson M. ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. Pharmgenomics Pers Med. 2018;11:147–155.
   PubMed Web of Science ®Google Scholar
• Doshi S, Ray D, Stein K, et al. Economic analysis of alternative strategies for detection of ALK rearrangements in non small cell lung cancer. Diagnostics (Basel). 2016;6(1):4.
   Google Scholar
• Lambros L, Guibourg B, Uguen A. Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: about different strategies in France. Cancer Cytopathol. 2017;125(11):876.
   PubMed Web of Science ®Google Scholar
• Lu S, Yu Y, Fu S, et al.. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. PLoS One. 2018;13(10):e0205827.
   PubMed Web of Science ®Google Scholar
• Letovanec I, Finn S, Zygoura P, et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European thoracic oncology platform lungscape project. J Thorac Oncol. 2018;13:413–425 3
   PubMed Web of Science ®Google Scholar
• Yu TM, Morrison C, Gold EJ, et al.. Budget Impact of next-generation sequencing for molecular assessment of advanced non-small cell lung cancer. Value Health. 2018;21(11):1278–1285.
   PubMed Web of Science ®Google Scholar
• Huang RSP, Gottberg-Williams A, Vang P, et al. Correlating ROS1 protein expression with ROS1 fusions, amplifications, and mutations. JTO Clin Res Rep 2021;2:1–9 2
   Google Scholar
• Belli C, Penault-Llorca F, Ladanyi M, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol. 2021;32:337–350. 3
   PubMed Web of Science ®Google Scholar
• Solomon JP, Hechtman JF. Detection of NTRK fusions: merits and limitations of current diagnostic platforms. Cancer Res. 2019;79:3163–3168. 13
   PubMed Web of Science ®Google Scholar